Chengdu Easton Biopharmaceuticals Co., Ltd. (SHA:688513)
China flag China · Delayed Price · Currency is CNY
57.95
+2.59 (4.68%)
At close: Mar 6, 2026

SHA:688513 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
1,3311,3481,1161,1701,023
Other Revenue
-1.841.420.630.07
1,3311,3501,1171,1711,023
Revenue Growth (YoY)
-1.36%20.82%-4.56%14.43%10.96%
Cost of Revenue
-345.23226.94199.11146.32
Gross Profit
1,3311,005890.18971.4876.62
Selling, General & Admin
-552.93483.43564.44528.06
Research & Development
-262.77237.45229.99199.59
Other Operating Expenses
1,01917.3717.4618.1515.75
Operating Expenses
1,019836.11737.98814741.14
Operating Income
312.52168.42152.2157.4135.47
Interest Expense
--3.68-3.42-2.61-0.36
Interest & Investment Income
-27.3825.6120.6932.83
Currency Exchange Gain (Loss)
-0.1600.030.02
Other Non Operating Income (Expenses)
-13.140.28-0.1-0.11-0.19
EBT Excluding Unusual Items
299.38192.56174.29175.41167.77
Gain (Loss) on Sale of Investments
-14.9214.5719.9913.69
Gain (Loss) on Sale of Assets
--0.110.030.19-0.1
Other Unusual Items
-45.2252.7666.465.56
Pretax Income
299.38252.59241.64261.99246.92
Income Tax Expense
16.1314.3515.0715.4714.49
Net Income
283.25238.23226.57246.52232.43
Net Income to Common
283.25238.23226.57246.52232.43
Net Income Growth
18.89%5.15%-8.09%6.06%30.46%
Shares Outstanding (Basic)
174175177177176
Shares Outstanding (Diluted)
174175177177176
Shares Change (YoY)
-0.80%-1.04%0.14%0.37%19.70%
EPS (Basic)
1.631.361.281.391.32
EPS (Diluted)
1.631.361.281.391.32
EPS Growth
19.85%6.25%-8.22%5.68%8.98%
Free Cash Flow
-145.8299.99-187.38-122.59
Free Cash Flow Per Share
-0.830.56-1.06-0.70
Dividend Per Share
-0.4300.3950.3810.531
Dividend Growth
-8.97%3.57%-28.19%159.97%
Gross Margin
100.00%74.42%79.68%82.99%85.70%
Operating Margin
23.47%12.48%13.62%13.45%13.24%
Profit Margin
21.27%17.65%20.28%21.06%22.72%
Free Cash Flow Margin
-10.80%8.95%-16.01%-11.98%
EBITDA
393.89249.79225.43215.75168.08
EBITDA Margin
29.59%18.51%20.18%18.43%16.43%
D&A For EBITDA
81.3781.3773.2358.3532.6
EBIT
312.52168.42152.2157.4135.47
EBIT Margin
23.47%12.48%13.62%13.45%13.24%
Effective Tax Rate
5.39%5.68%6.24%5.90%5.87%
Revenue as Reported
-1,3501,1171,1711,023
Advertising Expenses
---403393.56
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.